Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) CEO Lloyd Mitchell Segal sold 2,650 shares of the firm's stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $4.63, for a total value of $12,269.50. Following the completion of the sale, the chief executive officer now directly owns 83,866 shares of the company's stock, valued at $388,299.58. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Lloyd Mitchell Segal also recently made the following trade(s):
- On Monday, March 25th, Lloyd Mitchell Segal sold 2,650 shares of Repare Therapeutics stock. The stock was sold at an average price of $4.79, for a total value of $12,693.50.
Repare Therapeutics Trading Up 3.1 %
Shares of RPTX opened at $4.67 on Thursday. The firm has a market cap of $172.79 million, a P/E ratio of -2.09 and a beta of 0.62. The company's 50-day moving average price is $6.33 and its 200 day moving average price is $6.60. Repare Therapeutics Inc. has a 12-month low of $3.08 and a 12-month high of $13.85.
Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.11). The business had revenue of $13.05 million for the quarter, compared to analysts' expectations of $15.92 million. Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. Equities research analysts forecast that Repare Therapeutics Inc. will post -2.74 earnings per share for the current year.
Institutional Trading of Repare Therapeutics
Exposed: 10 CENT Crypto to Explode April 20th?
From True Market Insiders | Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%...
Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
A number of institutional investors and hedge funds have recently bought and sold shares of RPTX. Barclays PLC purchased a new stake in Repare Therapeutics during the second quarter worth about $36,000. Deutsche Bank AG purchased a new stake in Repare Therapeutics during the fourth quarter worth about $40,000. UBS Group AG increased its stake in Repare Therapeutics by 26.3% during the third quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after purchasing an additional 739 shares during the period. Wells Fargo & Company MN increased its stake in shares of Repare Therapeutics by 185.8% during the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company's stock worth $45,000 after buying an additional 1,977 shares during the period. Finally, SRS Capital Advisors Inc. purchased a new stake in shares of Repare Therapeutics during the first quarter worth approximately $49,000. 85.09% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have issued reports on RPTX shares. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Repare Therapeutics in a research note on Wednesday, February 21st. Bloom Burton lowered shares of Repare Therapeutics from a "buy" rating to an "accumulate" rating in a report on Tuesday, February 13th.
Read Our Latest Report on Repare Therapeutics
Repare Therapeutics Company Profile
(
Get Free Report)
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
